首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Chemotherapy Plays a Major Role in the Inhibition of Catch-up Growth During Maintenance Therapy for Childhood Acute Lymphoblastic Leukemia
【24h】

Chemotherapy Plays a Major Role in the Inhibition of Catch-up Growth During Maintenance Therapy for Childhood Acute Lymphoblastic Leukemia

机译:化学疗法在抑制急性急性淋巴细胞白血病的维持治疗过程中在追赶生长中起主要作用

获取原文
       

摘要

Objective . In children treated for acute lymphoblastic leukemia (ALL), catch-up growth occurs after cessation of therapy and not during maintenance therapy. In this study we investigated whether this inhibition of catch-up growth during maintenance treatment is attributable to the influence of chemotherapy or to the influence of corticosteroids.Patients . Forty-six children treated for ALL were included in the study. In 27 patients maintenance therapy comprised vincristine (VCR), prednisone (Pred), or dexamethasone (Dexa) alternated with 6-mercaptopurine (6-MP) and methotrexate (MTX) and 19 patients received maintenance therapy with 6-MP and MTX only. Treatment did not include cranial irradiation.Results . Statural growth during maintenance treatment was comparable in both groups over the study period of 1.5 years.Conclusion . Chemotherapy with 6-MP and MTX, and not corticosteroids, is the main factor that prevents catch-up growth from occurring during maintenance therapy for ALL.
机译:目标。在接受急性淋巴细胞白血病(ALL)治疗的儿童中,追赶性生长发生在停止治疗后而非维持治疗期间。在这项研究中,我们调查了维持治疗期间这种对追赶性生长的抑制是归因于化疗的影响还是归因于皮质类固醇的影响。本研究包括接受ALL治疗的46名儿童。在27例患者中,维持治疗包括长春新碱(VCR),泼尼松(Pred)或地塞米松(Dexa)与6-巯基嘌呤(6-MP)和甲氨蝶呤(MTX)交替使用,而19例患者仅接受6-MP和MTX维持治疗。治疗不包括颅骨照射。在1.5年的研究期间,两组维持治疗期间的体形增长相当。使用6-MP和MTX而非皮质类固醇的化学疗法是防止ALL维持疗法期间发生追赶性生长的主要因素。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号